A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer

Baruch Brenner, Michal Sarfaty, Ofer Purim, Yulia Kundel, Limor Amit, Amir Abramovich, Udi Sadeh Gonik, Efraim Idelevich, Noa Gordon, Gal Medalia, Aaron Sulkes, Baruch Brenner, Michal Sarfaty, Ofer Purim, Yulia Kundel, Limor Amit, Amir Abramovich, Udi Sadeh Gonik, Efraim Idelevich, Noa Gordon, Gal Medalia, Aaron Sulkes

Abstract

Introduction: Current treatment options for advanced esophagogastric cancer (AEGC) are still unsatisfactory. The aim of this prospective phase Ib/II study was to evaluate the safety and efficacy of a novel regimen, AVDCX, consisting of weekly docetaxel and cisplatin together with capecitabine and bevacizumab, in AEGC.

Methods: Patients with AEGC received treatment with different dose levels of AVDCX (cisplatin and docetaxel 25-35 mg/m2, days 1,8, capecitabine 1,600 mg/m2 days 1-14, bevacizumab 7.5 mg/kg, day 1, Q:21 days). The study's primary objectives were to establish the recommended phase II doses of docetaxel and cisplatin in AVDCX (phase Ib part) and to determine the tumor response rate (phase II part).

Results: The study was closed early, after the accrual of 22 patients, due to accumulating toxicity-related deaths. The median age was 59 years and 77% of patients had gastric or gastroesophageal adenocarcinomas. Grade ≥3 adverse events were documented in 18 patients (82%), usually neutropenia (36%), fatigue (54%) or diarrhea (23%). There were three fatal toxicities (14%): mesenteric thromboembolism, gastric perforation and pancytopenic sepsis. The recommended phase II doses of cisplatin and docetaxel were determined to be 25 mg/m2 and 30 mg/m2, respectively. Twenty-one patients were evaluable for response: 12 (54%) had partial response (PR), 4 (18%) had stable disease (SD) and none had complete response (CR). Hence, the objective response rate (CR+PR) was 54% and the disease control rate (CR+PR+SD) was 72%. For the 17 patients treated at the MTD, the objective response rate was 41% and the disease control rate was 88%. The median overall survival (OS) for these patients was 13.9 months (range, 1.5-52.2 months) and the median progression-free survival was 7.6 months (range, 1.3-26.6 months). The 2-year OS rate reached 23.7%.

Conclusions: AVDCX was associated with a high rate of regimen related fatal adverse events and is not appropriate for further development in AEGC patients.

Trial registration: ClinicalTrials.gov NCT00845884.

Conflict of interest statement

Competing Interests: The study was supported by Roche and Sanofi-Aventis pharmaceuticals, which supplied the study drugs and funded the statistical analysis. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This did not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1. CONSORT Flow Diagram.
Fig 1. CONSORT Flow Diagram.
Fig 2. Progression-free survival (PFS) and overall…
Fig 2. Progression-free survival (PFS) and overall survival (OS).

References

    1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. Journal of clinical oncology. 2006;24(14):2137–50.
    1. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;3(3).
    1. Correa P. The epidemiology of gastric cancer. World journal of surgery. 1991;15(2):228–34.
    1. Franceschi S, Levi F, La Vecchia C. Epidemiology of gastric cancer in Europe. European Journal of Cancer Prevention. 1994;3:5–10.
    1. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Journal of Clinical Oncology. 2000;18(14):2648–57.
    1. Kundel Y, Purim O, Figer A, Stemmer SM, Tichler T, Sulkes J, et al. Weekly infusional high-dose 5-fluorouracil and leucovorin and biweekly cisplatin: A convenient treatment option in advanced gastric cancer. American Journal of Case Reports. 2008;14(4):CR190–CR5.
    1. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. Journal of Clinical Oncology. 2006;24(31):4991–7.
    1. Tabernero J, Climent M, Lluch A, Albanell J, Vermorken J, Barnadas A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Annals of oncology. 2004;15(9):1358–65.
    1. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt E-W, et al. Phase III study of second-line chemotherapy for advanced non–small-cell lung cancer with weekly compared with 3-weekly docetaxel. Journal of Clinical Oncology. 2005;23(33):8389–95.
    1. Sparano J, Wang M, Martino S, Jones V, Perez E, Wolff A. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: results of Intergroup Trial E1199. J Clin Oncol. 2007;25(Suppl20):516.
    1. Tebbutt N, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, et al. ATTAX: Randomised phase II study evaluating weekly docetaxel-based chemotherapy combinations in advanced esophago-gastric cancer, final results of an AGITG trial. J Clin Oncol. 2007;25(18S):4528.
    1. Moehler M, Thuss-Patience P, Arnold D, Grothe W, Stein A, Seufferlein T, et al. Docetaxel, oxaliplatin, and capecitabine (TEX regimen) for patients with metastatic gastric cancer: Interim results from a phase II trial by the German AIO Group. J Clin Oncol. 2009;27(15S):4554.
    1. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. Journal of Clinical Oncology. 2001;19(21):4097–106.
    1. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. Journal of Clinical Oncology. 2001;19(8):2282–92.
    1. O'shaughnessy J, Blum J, Moiseyenko V, Jones S, Miles D, Bell D, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Annals of Oncology. 2001;12(9):1247–54.
    1. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. New England Journal of Medicine. 2008;358(1):36–46. 10.1056/NEJMoa073149
    1. Kang Y-K, Kang W-K, Shin D-B, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Annals of oncology. 2009;20(4):666–73. 10.1093/annonc/mdn717
    1. O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub J-P, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology. 2002;20(12):2812–23.
    1. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clinical Cancer Research. 1998;4(4):1013–9.
    1. Thuss-Patience P, Kretzschmar A, Dogan Y, Blau I, Pink D, Lebedinzew B, et al. Capecitabine and docetaxel for advanced gastric cancer. J Clin Oncol. 2006;24(18):4068.
    1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England journal of medicine. 2004;350(23):2335–42.
    1. Sandler A, Gray R, Brahmer J, Dowlati A, Schiller J, Perry M, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC# 704865) in patients with advanced non squamous non small cell 24lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial E4599. J Clin Oncol. 2005;23.
    1. Zon R, Wang M, Gralow J, Dickler M, Cobleigh M, Perez E, et al. A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern Cooperative Oncology Group trial E2100. European Journal of Cancer Supplements. 2006;4(2):47.
    1. Miller KD. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clinical breast cancer. 2003;3(6):421–2.
    1. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. Journal of Clinical Oncology. 2006;24(33):5201–6.
    1. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology. 2011;29(30):3968–76. 10.1200/JCO.2011.36.2236
    1. Shen L, Li J, Xu J, Pan H, Dai G, Qin S, et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2014:1–9.
    1. Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer S. The impact of bevacizumab (avastin) on survival in metastatic solid tumors-a meta-analysis and systematic review. PloS one. 2013;8(1):e51780 10.1371/journal.pone.0051780
    1. Lyman GH, Eckert L, Wang Y, Wang H, Cohen A. Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. The oncologist. 2013;18(12):1321–9 10.1634/theoncologist.2013-0226
    1. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. Jama. 2011;305(5):487–94. 10.1001/jama.2011.51
    1. Sparano J, Wang M, Martino S, Jones V, Perez E, Saphner T, et al., editors. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: results of Intergroup Trial E1199. ASCO Annual Meeting Proceedings; 2007.
    1. Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, et al. Phase 3 study comparing the use of docetaxel on an every‐3‐week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 2008;112(7):1455–61. 10.1002/cncr.23321
    1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine. 2004;351(15):1502–12.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir